Hui‐Peng Lee

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 448 citations · Full text

Medicine, Hematology, Pharmacology +4

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Meletios Α. Dimopoulos, Stephen Opat, Shirley D’Sa et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Hematology, Pharmacology +11

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

Meletios Α. Dimopoulos, Ramón García‐Sánz, Hui‐Peng Lee et al. · Blood Advances · 2020 · 78 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)

Morton Coleman, David Belada, Olivier Casasnovas et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacology +14

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the <scp>COVID</scp>‐19 pandemic

Pietro R Di Ciaccio, Georgia McCaughan, Judith Trotman et al. · Internal Medicine Journal · 2020 · 43 citations · Full text

Medicine, Infectious Diseases, Oncology +15